Search - tctmd.com

Displaying 1 - 20 of 48

Sort: Relevancy | Date

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

News Daily News

Crushing It: Cangrelor and Ticagrelor Can Be Used Together Safely in STEMI, Small Study Hints

Todd Neale

January 14, 2019

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Daily News

尽管没有随机对照试验，但倾向得分匹配分析为导管室选择坎格雷洛和GPI提供了指导

Yael L. Maxwell

December 06, 2016

News Daily News

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Yael L. Maxwell

December 06, 2016

News Daily News

Sin ECA, el Análisis de Emparejamiento por Puntuación de la Propensión permite tomar una Decisión Informada entre Cangrelor y GPI en el Laboratorio de Cateterización

Yael L. Maxwell

December 06, 2016

News Conference News ESC 2016

Day or Night, STEMI Patients Receive Similar Levels of Quality Care

L.A. McKeown

August 31, 2016

Presentation ESC 2016

“Off Hours” Versus “On Hours” Presentation in ST-Segment Elevation Myocardial Infarction: Findings from CHAMPION PHOENIX

Presenter: Deepak L. Bhatt

August 31, 2016

News Opinion Conversations in Cardiology

Conversations in Cardiology: Post-PCI Clopidogrel in CHAMPION PHOENIX Trial of Cangrelor

February 08, 2016

Presentation TCT 2015

TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics The CHAMPION PHOENIX Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Gregg W. Stone

October 13, 2015

Presentation TCT 2015

TCT 75: Cangrelor Improves Ischemic Outcomes in Patients With Multivessel Disease and Single Vessel Disease Undergoing PCI Insights From the CHAMPION PHOENIX Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Freddy Abnousi

October 13, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Daily News

在PCI患者中切入部位和坎格雷洛之间没有相互作用

Caitlin E. Cox

October 06, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Caitlin E. Cox

October 06, 2015

Presentation

CHAMPION PHOENIX: Effect of Cangrelor and Access Site on Ischemic and Bleeding Events

Presenter: JA. Gutierrez

October 05, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Daily News

La Aprobación de la FDA de Cangrelor Amplía las Opciones Antiplaquetarias para la PCI

Todd Neale

June 29, 2015

News Daily News

FDA 批准坎格雷洛作为 PCI 的抗血小板治疗方案

Todd Neale

June 29, 2015

Advertisement

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Crushing It: Cangrelor and Ticagrelor Can Be Used Together Safely in STEMI, Small Study Hints

ESC Updates Guidelines for Treating STEMI Patients

尽管没有随机对照试验，但倾向得分匹配分析为导管室选择坎格雷洛和GPI提供了指导

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Sin ECA, el Análisis de Emparejamiento por Puntuación de la Propensión permite tomar una Decisión Informada entre Cangrelor y GPI en el Laboratorio de Cateterización

Day or Night, STEMI Patients Receive Similar Levels of Quality Care

“Off Hours” Versus “On Hours” Presentation in ST-Segment Elevation Myocardial Infarction: Findings from CHAMPION PHOENIX

Conversations in Cardiology: Post-PCI Clopidogrel in CHAMPION PHOENIX Trial of Cangrelor

TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics The CHAMPION PHOENIX Trial

TCT 75: Cangrelor Improves Ischemic Outcomes in Patients With Multivessel Disease and Single Vessel Disease Undergoing PCI Insights From the CHAMPION PHOENIX Trial

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

在PCI患者中切入部位和坎格雷洛之间没有相互作用

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

CHAMPION PHOENIX: Effect of Cangrelor and Access Site on Ischemic and Bleeding Events

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

La Aprobación de la FDA de Cangrelor Amplía las Opciones Antiplaquetarias para la PCI

FDA 批准坎格雷洛作为 PCI 的抗血小板治疗方案

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content